Cash Flow Statement

Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Shares Issued Shares Repurchased

Growth Metrics

Ratios

Avai Bio (AVAI) Capital Expenditures (2019 - 2021)

Avai Bio's Capital Expenditures history spans 2 years, with the latest figure at $122550.0 for Q4 2020.

On a quarterly basis, Capital Expenditures changed N/A to $122550.0 in Q4 2020 year-over-year; TTM through Dec 2020 was $122931.0, a 375.78% increase, with the full-year FY2021 number at $114.0, changed N/A from a year prior.
Capital Expenditures hit $122550.0 in Q4 2020 for Avai Bio, up from $601.0 in the prior quarter.
Over the last five years, Capital Expenditures for AVAI hit a ceiling of $122550.0 in Q4 2020 and a floor of -$220.0 in Q2 2020.